Perhaps the greatest milestone in 2016 came when Dr. Uday Bhanu Maachani established two gliomatosis cerebri cell cultures from living patients. From one of these lines he created a xenograft: A mouse model with a GC tumor sampled from an actual patient. This is the only animal model anywhere in the world with a GC tumor cultured from a patient. Read more
The Children’s Brain Tumor Project made amazing progress this year, not only in terms of what we learned but also in what we shared. The fact is, getting our discoveries out into the scientific community is just as important as making them in the first place. Research is such an iterative process—we make a small but significant finding and share it by publishing an academic paper read by colleagues around the world, which they then use to advance their own work. They publish their new findings, which we then read and use to inspire our next steps. Back and forth, one step at a time, we move the science forward.
That’s why 2016 was such a big year for us. We made some very interesting findings, but we also concentrated on sharing them. The Internet is a big help here, since it shortens the time it takes to disseminate information. An accepted paper can spend months in the queue for publication, but academic journals now publish electronically in advance of print. That gets our findings into circulation much faster, and it also lets us learn from other labs in a more timely way. Read more
There’s an old adage that says if you want to go fast, go alone; if you want to go far, go together. Research science rarely adheres to that—investigators spend a lot of lonely hours peering into microscopes and scrolling through endless data points, all in the hope that someday all that solo work will add up to a breakthrough. We often go alone, and go far, but usually not fast.
The Children’s Brain Tumor Project has also defied that adage in that we are going fast, but together. This requires teamwork like no other—we need other labs at Weill Cornell, tissue banks around the country, and other scientists comparing notes and sharing findings—because we know we need to move quickly, and get far. Read more
Thanks to a number of grants and private donations, in July and August the CBTP lab team was joined by several young researchers working on specific projects to advance the field of pediatric neuro-oncology. This “summer sprint” was an unprecedented effort that produced some excellent results.
Umberto Tosi, funded by a POST grant from the Alex’s Lemonade Stand Foundation, worked on a project to improve the measurement of drug delivery to the brain via “theranostic” (therapeutic and diagnostic) agents.
The usual method of determining whether a drug has been successfully delivered is to wait for a clinical response, a “wait-and-see” approach that is neither timely nor precise. If researchers could modify a drug to make it fluorescent—and therefore visible on PET or MRI imaging—they would be able to see in real time whether that drug has reached its target. The key is to make delivery of the drug visible and measurable without reducing its effectiveness. Read more
As many of you probably read about on Facebook, on September 8 we treated the final patient in our Phase I clinical trial of convection-enhanced delivery (CED) for diffuse intrinsic pontine glioma (DIPG). The trial, which had enrolled 27 patients over the past four years, was designed to test the safety of CED as a means of delivering a cancer-fighting drug directly to the site of a DIPG tumor. Four patients received a second infusion, bringing the total number of treatments to 31. Read more
“Exploring the role of inflammation in the malignant transformation of low-grade gliomas.” Journal of Neuroimmunology, 2016 Aug 15;297:132-40. Epub 2016 May 25.
“A novel magnetic resonance imaging segmentation technique for determining diffuse intrinsic pontine glioma tumor volume.” Journal of Neurosurgery, Pediatrics, 2016 Jul 8:1-8. [Epub ahead of print]
“A Novel Methodology for Applying Multivoxel MR Spectroscopy to Evaluate Convection-Enhanced Drug Delivery in Diffuse Intrinsic Pontine Gliomas.” AJNR American Journal of Neuroradiology, 2016 Jul;37(7):1367-73. Epub 2016 Mar 3.
“Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France.” Pediatric Blood Cancer, 2016 Jul 28. [Epub ahead of print]
“Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.” Current Neuropharmacology, 2016 Jun 13. [Epub ahead of print]
“Clinical Genomics: Challenges and Opportunities.” Critical Reviews in Eukaryotic Gene Expression, 2016;26(2):97-113.
Click on any of the links above to read summaries of these papers on PubMed.com
This summer is going to be an amazing one in the Children’s Brain Tumor Project laboratory. Thanks to grants and gifts from families and foundations, we will have six summer researchers conducting several different lines of investigations, which will give our research a tremendous boost.
One thing we’ve known from the beginning of our research on pediatric brain tumors is that none of us will be able to do this alone. We must work too fast, and find answers too quickly, to operate in silos. The old model, in which researchers guard their work carefully until they publish results, simply won’t work. Read more
Thanks to the generosity of a number of donors, the summer of 2016 will be an unprecedented one at the Children’s Brain Tumor Project (CBTP). With grants and gifts from families and foundations, the CBTP plans to fill the lab with an impressive array of summer students and fellows conducting research at an amazing pace. The newly funded summer positions are:
St. Baldrick’s Summer Fellows: Emilie George and Raymond Chang will be testing new drugs and drug combinations against gliomatosis cerebri and DIPG, funded by a summer fellowship grant from the St. Baldrick’s Foundation. (More about that grant)
It will be four years in May since Dr. Souweidane treated the very first patient in his clinical trial testing the safety of convection-enhanced delivery (CED) of 124I-8H9 against DIPG. (The 8H9 antibody has been shown to bind to the tumor, and 124I kills cancer cells with radiation.) The trial was originally expected to last for two years and treat12 DIPG patients at four dose levels; in 2014 the FDA approved an extension of the trial to seven dose levels. Dr. Souweidane is currently treating patients at the seventh dose level, and has re-treated several children. There have been no adverse effects on any child. Read more